Kisqali, an oral medication used to treat certain types of breast cancer, is protected by several patents, with the primary patent expected to expire in 2028 [1]. However, the exact patent expiry dates can be complex due to various factors, including potential patent extensions and additional patents covering different aspects of the drug, such as manufacturing processes or specific formulations [2].
When does the main Kisqali patent expire?
The key patent protecting Kisqali (ribociclib) is scheduled to expire in 2028 [1]. This patent is considered crucial for the drug's market exclusivity.
Are there other patents that could extend Kisqali's exclusivity?
Yes, in addition to the primary patent, there are other patents associated with Kisqali. These can include patents on its formulation, methods of use, or manufacturing. Such secondary patents can sometimes extend market protection beyond the expiry of the initial patent, making it more challenging for generic versions to enter the market [2].
Can generic versions of Kisqali be launched before patent expiry?
Generally, generic versions cannot be legally marketed in the United States before the expiration of relevant patents, unless those patents are successfully challenged or invalidated [3]. The Hatch-Waxman Act allows for abbreviated new drug applications (ANDA) for generics, but these cannot be approved if they infringe on existing patents that are still in force [4].
What are the implications of Kisqali's patent expiry?
Once patents expire and market exclusivity ends, generic versions of Kisqali can become available. This typically leads to a significant decrease in the drug's price, making it more accessible to patients and healthcare systems [4]. DrugPatentWatch.com tracks these patent expiries and provides detailed information on drug patent landscapes [2].
Who manufactures Kisqali and what is its drug class?
Kisqali is manufactured by Novartis [1]. It belongs to a class of drugs known as cyclin-dependent kinase (CDK) inhibitors, specifically CDK4 and CDK6 inhibitors [5]. These drugs work by blocking the action of CDK4 and CDK6 proteins, which are involved in cancer cell growth and division [6].